A highly effective, injectable form of HIV pre-exposure prophylaxis (PrEP), lenacapavir (LEN), is now available in South Africa. This represents a significant advancement in HIV prevention, boasting near 100% effectiveness in clinical trials. Unlike daily oral PrEP, lenacapavir is administered via injection, potentially improving adherence. Experts emphasize the importance of integrating this new injectable PrEP into existing sexual and reproductive health services for optimal impact. Successful implementation will require coordination with broader healthcare systems. The arrival of lenacapavir offers renewed hope in the fight against HIV transmission, particularly for individuals who struggle with or prefer not to take daily medication.